REG - Silence Therapeutics - Conference Participation

Silence TherapeuticsAnnouncement

01/10/2020 07:01

RNS Number : 6847A
  
Silence Therapeutics PLC
  
01 October 2020
  
 

Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference
 
1 October 2020
 
LONDON, Silence Therapeutics plc (AIM: SLN) and (Nasdaq: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that Mark Rothera, President and Chief Executive Officer, and Giles Campion, Head of R&D and Chief Medical Officer, will participate in a fireside chat at the Chardan Virtual 4th Annual Genetic Medicines Conference. The fireside chat will take place on Monday, October 5, 2020 at 14:00 EDT (19:00 BST).
 
A live webcast of the Company's fireside chat can be accessed via the Investors section of the Company's website at www.silence-therapeutics.com. An archived replay of the webcasts will be available for 90 days on the Company's website after the conference.
 
 
 
 
For more information, please contact:
 



Silence Therapeutics plc
Gem Hopkins, Head of IR & Corporate Communications
 
 


Tel:  +1 (646) 637-3208




Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 


Tel:  +44 (0)20 7597 5970




European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com 
 


Tel: +44 (0) 20 3709 5700




U.S. IR
Westwicke
Peter Vozzo
peter.vozzo@westwicke.com


 Tel: +1 (443) 213-0505



 
 
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCFLFFDAFIIVII